



# RISCC project - communication & dissemination

-----

**Claudia Robles**

30 Sep 2023 – Istanbul, Türkiye  
11th PATIENT ADVOCACY SEMINAR

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845






## Current situation in Europe

- ❑ Differences in prevention strategies / policies between regions
- ❑ In countries with an excellent score, there is still room for improvement

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845




# Current approach to Cervical Cancer screening



	Management	Risk
<b>CURRENT APPROACH</b>	Based on test result	Defined by test result = <b><i>One-size fits all</i></b>



# New approach to Cervical Cancer screening



	Management	Risk
<b>NEW APPROACH (Risk-based screening)</b>	Based on risk of cervical cancer	Based on test result, screening history, age, vaccination status, etc. = <b><i>Personalised prevention</i></b>





# Advantages of risk-based cervical cancer screening

## FOR WOMEN:

- ❑ Less unnecessary activity in low-risk women = lower rates of anxiety and overtreatment
- ❑ Expedited follow-up of women at higher risk = earlier diagnosis

## FOR ADMINISTRATIONS / GOVERNMENTS:

- ❑ Equal management at equal risk = easier incorporation of new screening methods
- ❑ Cost reduction of screening programs = Up to 100,000 million euros per year
- ❑ Cost-effective (more health benefits at equal or lower cost) = +2€ per woman avoids 12.500 annual cervical cancer deaths in Europe


This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845





# RISCC project: *Risk-based Screening for Cervical Cancer*

**AIM:** To develop the first European risk-based cervical cancer screening proposal



For more information: <https://www.riscc-h2020.eu>

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845





# RISCC project: *Risk-based Screening for Cervical Cancer*

**AIM:** To develop the first European risk-based cervical cancer screening proposal

Assess the **cost-effectiveness** of risk-based cervical cancer screening programs



Conduct a ***pilot*** risk-based screening program for cervical cancer in Europe

## IMPLEMENTATION TOOLS



Develop and provide ***open-source IT tools*** to facilitate clinical management



Offer free online **training** for personnel involved in screening programs & dissemination/communication activities

For more information: <https://www.riscc-h2020.eu>

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845





## RISCC results so far

- Estimation of risks:
  - An ever positive HPV result results in higher lifetime risk
- Guidelines and opportunities in cervical cancer screening:
  - Use of HPV test over 30 years old
  - Implementation of self-sampling
  - 2-times triage of HPV positive women (now and in 12 months)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845







# RESULTS SO FAR

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845



## HPV tests

- ❑ Only use validated HPV tests (n=13 DNA tests and 1 mRNA test)
- ❑ Validated for:
  - Grouped vs extended genotyping tests
  - Physician-taken sample vs self-collected
  - Cervical vs vaginal vs urine
  - Irrespective of sampling device used
  
- ❑ HPV tests can be obtained at lower cost using high-volume procurements





# Self-sampling

- ❑ Updated data on compared performance of self-collected vs clinician samples; meta-analysis + longitudinal data
- ❑ Updated data on participation of women when offered self-sampling; meta-analysis + single studies
- ❑ First real-world performance data in the Netherlands – aspects to be checked to achieve adequate clinical accuracy

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845





# Management of HPV positive women

- ❑ Similar performance of p16 staining, extended genotyping and viral load in comparison to cytology
- ❑ Methylation test in HPV positive women with low grade cytology allows to reduce colposcopy referrals (costs) with no changes in CIN3+ detection rates
- ❑ In Norway, partial genotyping might provide the best benefit/referral ratio, thinking ahead on vaccinated women
- ❑ A combined triage with HPV genotyping, cytology and dual staining offers higher protection against future lesions





# Management of women with lesions

- Use of methylation testing could:
  - Identify women with lesions that do not require treatment
  - Predict lesions at a higher risk of progression in vaccinated women

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845





# COMMUNICATION AND DISSEMINATION

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845



# HPV related tumors e-learning program



## Targeted to specific professionals

Epidemiology and prevention of HPV diseases for primary care physicians

2519 8h



## Cervical Cancer Prevention

Strategies in primary and secondary prevention of cervical cancer

5657 12h

Cervical cancer prevention course - CLOSED

17336 15h



## HPV Vaccines

HPV Vaccine safety – Colombian edition

10983 10h

The Value of Vaccines & the importance of building vaccine confidence

3170 3h

HPV vaccines

2684 30h

Since Nov 2022

Update on Cervical cancer screening & Risk based screening

2821 40h

Since June 2021

[www.e-oncologia.org](http://www.e-oncologia.org)

BASIC

ADVANCED



## Dissemination

**HPWWorld**  
The newsletter on Human Papillomavirus

239 HPV ARTICLES	2281044 READS	345 CONTRIBUTORS
---------------------	------------------	---------------------

**FREE**  
subscription

**HPW**  
The newsletter on HPV

<https://www.hpworld.com>

Simplified summaries of scientific papers in 600 words for healthcare professionals

➔ Currently preparing an issue with RISCC and other European findings on cervical cancer prevention

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845








## Other actions on dissemination

- Social media - Twitter
- Newsletters
- Website
- Scientific papers and conferences presentations
- Commissioned article in EU RESEARCH
- Currently preparing a roundtable at the European parliament with other EU-funded projects
- Participating in the Results Booster platform

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845



# Roundtable: RISCC project - best practice sharing



## □ Main messages are:

- Implement HPV screening
- Use self-sampling
- Consider going for risk-based screening in the near future

## □ Are we reaching the identified audiences?





*For more information about the project, visit our website:*

**[www.riscc-h2020.eu](http://www.riscc-h2020.eu)**

 @RISCC\_H2020

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845



# DISSEMINATION OBJECTIVES

## Women eligible for screening

- Raise awareness of **cervical cancer; its association to HPV and its prevention strategies.**
- Understand the **advantages of screening and, in particular, of risk-based screening.**
- Understand the **advantages of e-health and m-health applications.**

## General public

- Raise awareness on the **involvement of the European Commission in health promotion and the impact on society.**
- Raise awareness on the **project and understand how it aims to improve women's health.**

## Healthcare policy makers and politicians

- Understand the **short- and long-term advantages of risk-based cervical cancer screening.**
- Understand the current **limitations of current screening programs and the need to implement risk-based screening.**
- Understand the **feasibility to implement risk-based screening.**





# Initial ideas how to involve ENGAGe ambassadors

- ❑ **Boost communication on the project and regular updates** through your own communication tools (social networks, website, contact list, etc...)
- ❑ **Adapt communication materials**
  - Verify translations / Adapt key messages
  - Assess whether communication tools are adaptable to your country context
- ❑ **Fine-tune development of the e-health/m-health application**
  - If applicable

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845





# Initial ideas on what RISCC can do for the ambassadors

- ❑ **Boost visibility** of your association
- ❑ **Visibility of you as ambassador** on the [RISCC web](#) and social media
- ❑ **Connection** with **experts** in cervical cancer research in Europe
  - Training to improve knowledge on cervical cancer and HPV
  - Stay up-to-date on research
- ❑ **Connection** among other country ambassadors
  - Potential for cross-country collaboration

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847845

